Senti Operating Income from 2010 to 2026
| SNTI Stock | USD 0.95 0.02 2.15% |
Operating Income | First Reported 2010-12-31 | Previous Quarter -54.9 M | Current Value -57.7 M | Quarterly Volatility 22.4 M |
Check Senti Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senti Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 4.7 M or Selling General Administrative of 25.1 M, as well as many indicators such as Price To Sales Ratio of 16.18, Dividend Yield of 0.0 or PTB Ratio of 0.69. Senti financial statements analysis is a perfect complement when working with Senti Biosciences Valuation or Volatility modules.
Senti | Operating Income | Build AI portfolio with Senti Stock |
The Operating Income trend for Senti Biosciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Senti Biosciences is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Senti Biosciences' Operating Income Growth Pattern
Below is the plot of the Operating Income of Senti Biosciences over the last few years. Operating Income is the amount of profit realized from Senti Biosciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Senti Biosciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Senti Biosciences' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Senti Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Senti Operating Income Regression Statistics
| Arithmetic Mean | (36,468,939) | |
| Coefficient Of Variation | (61.46) | |
| Mean Deviation | 18,664,038 | |
| Median | (21,782,000) | |
| Standard Deviation | 22,413,838 | |
| Sample Variance | 502.4T | |
| Range | 70.9M | |
| R-Value | (0.75) | |
| Mean Square Error | 230.6T | |
| R-Squared | 0.57 | |
| Significance | 0.0005 | |
| Slope | (3,349,857) | |
| Total Sum of Squares | 8038.1T |
Senti Operating Income History
Other Fundumenentals of Senti Biosciences
Senti Biosciences Operating Income component correlations
Click cells to compare fundamentals
About Senti Biosciences Financial Statements
Investors use fundamental indicators, such as Senti Biosciences' Operating Income, to determine how well the company is positioned to perform in the future. Although Senti Biosciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Operating Income | -54.9 M | -57.7 M | |
| Non Operating Income Net Other | 9.6 M | 8.6 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Senti Biosciences Correlation against competitors. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is there potential for Biotechnology market expansion? Will Senti introduce new products? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Senti Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.